The estimated Net Worth of Jorge Md Plutzky is at least $22 mil dollars as of 31 October 2016. Jorge Plutzky owns over 3,125 units of VIVUS stock worth over $21,994 and over the last 11 years he sold VVUS stock worth over $0. In addition, he makes $0 as Independent Director at VIVUS.
Jorge has made over 3 trades of the VIVUS stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 3,125 units of VVUS stock worth $1,458 on 31 October 2016.
The largest trade he's ever made was exercising 3,125 units of VIVUS stock on 31 October 2016 worth over $1,458. On average, Jorge trades about 408 units every 3 days since 2013. As of 31 October 2016 he still owns at least 47,147 units of VIVUS stock.
You can see the complete history of Jorge Plutzky stock trades at the bottom of the page.
Dr. Jorge Plutzky M.D. serves as Independent Director of the Company. Dr. Plutzky has served as a director of the Company since May 9, 2013. Since 1996, Dr. Plutzky has served as the Director of The Vascular Disease Prevention Program, which includes the Lipid/Prevention Clinic, in the Cardiovascular Medicine Division at Brigham and Women's Hospital, where he is also Director of Preventive Cardiology. Since 1995, he has been on the faculty at Harvard Medical School and has directed a basic science laboratory focused on transcriptional mechanisms involved in adipogenesis, lipid metabolism, and diabetes, and their relationship to inflammation and atherosclerosis. Throughout his career, Dr. Plutzky has also been involved in translational clinical studies investigating links between metabolic disorders and cardiovascular disease. Dr. Plutzky has been a member of the scientific advisory boards of the Sarnoff Cardiovascular Research Foundation since 2009 and Ember Therapeutics since 2012. Dr. Plutzky has been elected to the American Society for Clinical Investigation and is a Fellow of the American College of Cardiology. Dr. Plutzky's papers have appeared in journals that include Science, PNAS, Diabetes, Lancet, Annals of Internal Medicine, and Nature Medicine. Dr. Plutzky has been involved with the U.S. Food and Drug Administration, serving both as a member of the Endocrinologic and Metabolic Drugs Advisory Committee and in advising and presenting for new drug application sponsors. He has been involved with both the American Heart Association and the American Diabetes Association. Dr. Plutzky has been recognized with the Eugene Braunwald Teaching Award, the University of Cologne's Klenk Lecture, Vanderbilt University's Rabin Lecture, Northwestern University's DeStevens Lecture and Harvard Medical School's Tucker Collins Lecture.
Jorge Plutzky is 61, he's been the Independent Director of VIVUS since 2013. There are 5 older and 4 younger executives at VIVUS. The oldest executive at VIVUS, Inc. is Edward Kangas, 75, who is the Independent Director.
Jorge's mailing address filed with the SEC is C/O VIVUS, INC., 900 E. HAMILTON AVE., SUITE 550, CAMPBELL,, CA, 95008.
Over the last 21 years, insiders at VIVUS have traded over $6,261,269 worth of VIVUS stock and bought 5,180,746 units worth $13,074,554 . The most active insiders traders include Tide Capital, Llc North Tid..., Alexander J Denner, eErnest Mario. On average, VIVUS executives and independent directors trade stock every 39 days with the average trade being worth of $35,394. The most recent stock trade was executed by John P. Amos on 1 March 2019, trading 11,000 units of VVUS stock currently worth $53,350.
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
VIVUS executives and other stock owners filed with the SEC include: